Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

e associated with a favorable settlement of a prior year's royalty dispute collected during the quarter, or $2.5 million net of tax benefit, resulting in a $0.03 per diluted share impact.

The Company's GAAP results for the second quarter of 2008 include amortization of $55.0 million, $23.6 million of restructuring charges, $7.2 million of stock-based compensation expense and a $0.3 million charge related to the write-up to fair market value of inventory acquired in connection with the acquisitions of Panbio Limited and BBI Holdings Plc. GAAP results for the second quarter of 2007 include amortization of $10.1 million, a $0.4 million restructuring charge, $47.3 million of non-cash stock-based compensation expense, of which $45.2 million relates to costs associated with stock option acceleration and conversion in connection with our acquisition of Biosite, Inc., a $1.2 million charge related to the write-up to fair market value of inventory acquired in connection with our accounting for the Biosite acquisition and $15.4 million of deferred financing costs and repayment premium related to the repayment of outstanding debt in conjunction with our financing arrangements related to our Biosite acquisition, offset by a $1.9 million foreign exchange gain on settlement of intercompany notes. These amounts, net of tax, have been excluded from the adjusted cash basis net income per common share for the respective quarters.

A detailed reconciliation of the Company's adjusted cash basis net income, which is a non-GAAP financial measure, to net loss under GAAP, as well as a discussion regarding this non-GAAP financial measure, is included in the schedules to this press release.

The Company will host a conference call beginning at 10:00 a.m. (Eastern Time) today, July 29, 2008, to discuss these results as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and o
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... LLC introduces HSP-A Soy Peptone. HSP A has been found ... ... (PRWEB) December 16, 2009 -- Nu-Tek BioSciences, LLC. ( ... HSP-A Soy Peptone. HSP-A, previously manufactured by Nutricepts, Inc. (Burnsville, ... to improve growth rates and yields. HSP-A has been found ...
(Date:12/15/2009)... Epeius Biotechnologies Corporation, an emerging leader ... international validation of the cutting-edge science behind its ... around the world rediscovered the Cyclin G1 ... cancer pathogenesis and disease progression, and thus a ... the NIH National Cancer Institute investigating the role ...
(Date:12/15/2009)... Corporation (Nasdaq: RGEN ) today announced that ... to support the ongoing development of new treatments ... (MDA). This grant will support the completion ... of a drug candidate for human clinical trials. ... important funding for Repligen,s research but it also ...
(Date:12/15/2009)... Reportlinker.com announces that a new market research ... The Future of Orphan Diseases ... Analysis and Reimbursement ,, ... Summary ,, The author has released ... Diseases Therapeutics - Market Forecasts to 2015, ...
Breaking Biology Technology:Scientists Rediscover Gene Target for Cancer Therapy 2Scientists Rediscover Gene Target for Cancer Therapy 3Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18
... China, May 6 /Xinhua-PRNewswire-FirstCall/ -- Benda,Pharmaceutical, Inc. ... producing both Gendicine(R), a commercialized gene,therapy medicine ... Chinese and,conventional medicines, today filed an amendment ... Securities and Exchange Commission ("SEC"). The,amendment covers ...
... Inc. (Nasdaq: CALP ) today announced that ... Care Conference in Boston,Massachusetts, will be webcast on ... President and CEO of Caliper, will be providing ... can be accessed at, http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CALP&item_id=18275 ,63. An archived ...
... Otsuka ... America Pharmaceutical, Inc., ROCKVILLE, Md., May 6 The American ... recipients of the fifth annual APF Awards for Advancing Minority,Mental Health. ... D.C. Each organization or individual was presented a plaque,along with an ...
Other Biology Technology:Benda Pharmaceutical Files Amendment To Form S-1 2American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 2American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 4American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 5
(Date:12/15/2009)... The 2009 Frost & Sullivan ... presented to Sagem Securite (Safran Group) for ... award recognises the company,s expertise in advanced ... offering novel, value-added products to end users. ... ,, "Sagem Securite has been involved in ...
(Date:12/15/2009)... brain diseases such as Alzheimer,s and Parkinson,s, doctors can ... help a patient. , But they come up empty-handed ... patients with ataxia disabling disorders that rob people ... neurologists are trying to change that with the help ... Institute of Neurological Disorders and Stroke to establish a ...
(Date:12/15/2009)... environmental impacts, social dynamics, and production levels are ... of an agroecosystem. Positive or negative, these factors ... social groups to continuously adapt farming and food ... learning theory suggests that knowledge is gained as ... are especially valuable for environmental and agricultural educators ...
Breaking Biology News(10 mins):Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4UF to lead national effort to help patients with rare brain disease 2UF to lead national effort to help patients with rare brain disease 3Experiential learning teaches change and adaptation 2Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates 55462 1Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates 55462 2Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates 55462 3Carnegie Mellon Researchers Develop Novel Tool to Rank Death Rates 55462 4UPDATE 3A Spokane Washington Man Indicted on Civil Rights Charges Related to Threats to Reproductive Health Services Clinic 55459 1California Life Science Business and Economic Development Experts Discuss Californias Bioscience Future 13708 1California Life Science Business and Economic Development Experts Discuss Californias Bioscience Future 13708 2
... Cincinnati, OH, August 13, 2008Dairy is recognized as a key ... it was unclear how long-term dairy intake contributes to the ... bone mineral content, and bone area. A new study ... investigates the effect of childhood dairy intake on adolescent ...
... hepatitis B infects 400 million people worldwide, many of ... B remains a stubborn, unrelenting health problem, especially in ... complications cause an estimated 1 million deaths globally each ... required for the current vaccines are costly and hard ...
... Ind. - Researchers have discovered an unusual molecule ... break down pollutants, especially the compounds that cause ... by this molecule, however, that will attract the ... University of Pennsylvania,s Edmund J. Kahn Distinguished Professor, ...
Other Biology News:Childhood dairy intake may improve adolescent bone health 2Nano vaccine for hepatitis B shows promise for third world 2Nano vaccine for hepatitis B shows promise for third world 3Strange molecule in the sky cleans acid rain, scientists discover 2Strange molecule in the sky cleans acid rain, scientists discover 3
...
... Spin Columns provide a rapid and simple method ... bp to 10 kb) from stained agarose gels ... excised from an agarose gel and loaded into ... the column are a series of membranes and ...
... The SpinPrep Gel DNA Kit enables efficient extraction ... bp in size from agarose gels. The procedure uses ... adsorption of the DNA to a silica membrane in ... purified DNA is eluted in low-salt buffer. Each spin ...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: